Incannex Healthcare INC 8-K filings

Incannex Healthcare Inc. announced the appointment of Dr. Charlene E. Gamaldo to its IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, strengthening its expertise ahead of anticipated Phase 2 data.

Incannex Healthcare Inc. has increased its at-the-market offering program capacity by an additional $100 million to enhance financial flexibility.

Incannex Healthcare Inc. announced the appointment of Dr. Douglas B. Kirsch to its IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, strengthening expertise for its late-stage development program.

Incannex Healthcare Inc. has achieved database lock for its RePOSA Phase 2 clinical trial of IHL-42X for obstructive sleep apnoea, on schedule, with top-line results anticipated in July 2025.

Incannex Healthcare Inc. has announced a 50:50 joint venture with Mind Medicine Australia to establish and operate a psychedelic-assisted therapies services clinic in Melbourne, aiming to significantly expand access and capacity for these treatments.

Incannex Healthcare Inc. has begun the process to transfer its common stock listing from The Nasdaq Global Market to The Nasdaq Capital Market in an effort to regain compliance with Nasdaq's continued listing requirements.

Incannex Healthcare Inc. has successfully cancelled all outstanding Series A Warrants, removing 347.2 million shares from potential future dilution, funded through its At-The-Market facility, and streamlining its capital structure ahead of critical Phase 2 clinical trial results for IHL-42X.

Incannex Healthcare Inc. announced the expansion of its IHL-42X Obstructive Sleep Apnea Clinical Advisory Board with the appointment of four distinguished industry and academic leaders, signaling a pivotal step towards late-stage development.

Incannex Healthcare Inc. announced FDA protocol clearance for its IHL-42X obstructive sleep apnea treatment to proceed to a streamlined U.S.-only Phase 3 clinical trial, building on strong Phase 2 momentum.

Incannex Healthcare Inc. has entered into an agreement to cancel its remaining Series A Warrants, removing up to 347.2 million shares from potential future dilution, strategically timed before the release of critical Phase 2 trial data for its lead drug candidate, IHL-42X.

Incannex Healthcare Inc. has significantly expanded its at-the-market (ATM) offering program by an additional $50 million, increased its authorized common stock to 800 million shares, and amended its equity incentive plan, while also detailing a strategy to cancel remaining Series A Warrants.

Incannex Healthcare Inc. strategically cancels a significant portion of its Series A warrants and raises $16.7 million through an at-the-market (ATM) facility to strengthen its shareholder position.

Incannex Healthcare Inc. has increased the maximum number of shares issuable under its sales agreement with A.G.P/Alliance Global Partners to $2,514,214.

Incannex Healthcare Inc. announced agreements that could reduce up to 50.4% of the shares underlying its Series A Warrants.

Incannex Healthcare modifies agreements with warrant holders to allow for an at-the-market offering, using proceeds to reduce warrant obligations.

Incannex Healthcare Inc. announced its fiscal third quarter 2025 financial results and provided business updates, highlighting progress in its IHL-42X development program for obstructive sleep apnea (OSA).

Incannex Healthcare Inc. announces the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study evaluating IHL-42X for obstructive sleep apnea (OSA), with topline results anticipated in July 2025.

Incannex Healthcare Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving the company until October 20, 2025, to regain compliance.

Incannex Healthcare Inc. has entered into a sales agreement with A.G.P./Alliance Global Partners for an at-the-market offering of its common stock, potentially raising up to $16,768,099, though immediate utilization is limited by prior agreements and share availability.

Incannex Healthcare announces the completion of Phase 2 patient enrollment in its RePOSA Phase 2/3 study of IHL-42X, an oral treatment for Obstructive Sleep Apnea (OSA), with topline data expected in the first half of 2025.

Incannex Healthcare Inc. fully repaid its outstanding convertible debenture to Arena Special Opportunities, leading to the termination of related agreements, while certain warrants remain in effect.

Incannex Healthcare secures $12.5 million through a private placement to fund clinical trials, including the IHL-42X Phase 2/3 Obstructive Sleep Apnea program.

Incannex Healthcare announced its fiscal second quarter 2025 financial results and provided business updates, highlighting positive pharmacokinetics findings for IHL-42X in treating Obstructive Sleep Apnea (OSA).

Incannex Healthcare appoints Alison Wimms, Ph.D., representing ResMed, to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board.

Incannex Healthcare reports positive topline results from a pharmacokinetics study of IHL-42X, an oral combination medicine for obstructive sleep apnea, demonstrating similar drug exposure to reference drugs.

Incannex Healthcare Inc. received a notification from Nasdaq regarding non-compliance with the minimum Market Value of Listed Securities requirement and is exploring options to regain compliance.

Incannex Healthcare's 2024 Annual Meeting saw the election of a director and approval of key proposals, including the ratification of the auditor and the issuance of stock related to financing agreements.

Incannex Healthcare has appointed Dr. Lou Barbato as Chief Medical Officer, bringing extensive experience in drug development and clinical strategy.

Incannex Healthcare has appointed Dr. Luigi M. Barbato as its Chief Medical Officer, effective October 21, 2024, with a base salary of $375,000 and other incentives.

Incannex Healthcare has finalized a $3.3 million secured convertible debenture agreement to advance its research and development pipeline and support operational growth.